239 related articles for article (PubMed ID: 10695732)
1. Immune defects observed in patients with primary malignant brain tumors.
Dix AR; Brooks WH; Roszman TL; Morford LA
J Neuroimmunol; 1999 Dec; 100(1-2):216-32. PubMed ID: 10695732
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors.
Morford LA; Dix AR; Brooks WH; Roszman TL
J Neurosurg; 1999 Dec; 91(6):935-46. PubMed ID: 10584838
[TBL] [Abstract][Full Text] [Related]
3. Modulation of T-cell function by gliomas.
Roszman T; Elliott L; Brooks W
Immunol Today; 1991 Oct; 12(10):370-4. PubMed ID: 1958290
[TBL] [Abstract][Full Text] [Related]
4. The role of regulatory T-cells in glioma immunology.
Ooi YC; Tran P; Ung N; Thill K; Trang A; Fong BM; Nagasawa DT; Lim M; Yang I
Clin Neurol Neurosurg; 2014 Apr; 119():125-32. PubMed ID: 24582432
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of immune evasion by gliomas.
Rolle CE; Sengupta S; Lesniak MS
Adv Exp Med Biol; 2012; 746():53-76. PubMed ID: 22639159
[TBL] [Abstract][Full Text] [Related]
6. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
Hishii M; Nitta T; Ishida H; Ebato M; Kurosu A; Yagita H; Sato K; Okumura K
Neurosurgery; 1995 Dec; 37(6):1160-6; discussion 1166-7. PubMed ID: 8584157
[TBL] [Abstract][Full Text] [Related]
7. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
8. [Characteristics and immunologic changes in patients with malignant brain tumors].
Khonina NA; Tsentner MI; Leplina OIu; Tikhonova MA; Stupak VV; Nikonov SD; Chërnykh ER; Ostanin AA
Vopr Onkol; 2002; 48(2):196-201. PubMed ID: 12227068
[TBL] [Abstract][Full Text] [Related]
9. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
[TBL] [Abstract][Full Text] [Related]
10. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
Jachimczak P; Bogdahn U; Schneider J; Behl C; Meixensberger J; Apfel R; Dörries R; Schlingensiepen KH; Brysch W
J Neurosurg; 1993 Jun; 78(6):944-51. PubMed ID: 8487077
[TBL] [Abstract][Full Text] [Related]
11. Similar immunity profiles in patients with meningioma and glioma tumors despite differences in the apoptosis and necrosis of circulating lymphocyte and monocyte populations.
Kataki A; Skandami V; Memos N; Nikolopoulou M; Oikonomou V; Androulis A; Konstadoulakis MM; Zografos CG
J Neurosurg Sci; 2014 Mar; 58(1):9-15. PubMed ID: 24614787
[TBL] [Abstract][Full Text] [Related]
12. In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect.
McVicar DW; Davis DF; Merchant RE
J Neurosurg; 1992 Feb; 76(2):251-60. PubMed ID: 1730954
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
Lussier DM; Woolf EC; Johnson JL; Brooks KS; Blattman JN; Scheck AC
BMC Cancer; 2016 May; 16():310. PubMed ID: 27178315
[TBL] [Abstract][Full Text] [Related]
14. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
15. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers.
Zou JP; Morford LA; Chougnet C; Dix AR; Brooks AG; Torres N; Shuman JD; Coligan JE; Brooks WH; Roszman TL; Shearer GM
J Immunol; 1999 Apr; 162(8):4882-92. PubMed ID: 10202033
[TBL] [Abstract][Full Text] [Related]
16. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Lemke D; Pfenning PN; Sahm F; Klein AC; Kempf T; Warnken U; Schnölzer M; Tudoran R; Weller M; Platten M; Wick W
Clin Cancer Res; 2012 Jan; 18(1):105-17. PubMed ID: 22080438
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
19. Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro.
Fries G; Perneczky A; Kempski O
Neurosurgery; 1994 Aug; 35(2):264-70; discussion 270-1. PubMed ID: 7969834
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor immune response: what are the roles for gliomas?].
Dietrich PY
Rev Neurol (Paris); 2001 Nov; 157(11 Pt 1):1339-48. PubMed ID: 11924003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
